NCT00749164

Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment

Allogeneic Mesenchymal Stem Cell Infusion for Treatment Of Steroid Resistant GVHD

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Now it is commonly accepted that MSC produce an immune-tolerant environment in different settings. It has been shown (mainly for BM-MSC) that MSC can down-regulate T cells activation. This characteristic of BM derived MSC already has clinical implications and shows their potent effectiveness both in prophylaxis and treatment of resistant GvHD. Ongoing clinical trials of use bone marrow MSC for treatment of steroid resistant GvHD are successfully run on and some bone marrow donor registries included BM-MSC as a material for donation. According to our preclinical studies MSC from cells from marrow, placenta, umbilical cord vessels demonstrate similar pronounced immunosuppressive effect both with autologous and allogeneic lymphocytes. Our preliminary clinical experience shows that BM-MSC is an effective tool for treatment of steroid resistant GVHD. Present study aimed to demonstrate if human UC-MSC has in vivo immunosuppressive effect and can be used for GVHD treatment

Conditions

• Graft-Versus-Host Disease

Interventions

Type	Name	Description
PROCEDURE	MSC transplantation	1-2X10\^6 MSC per kg

Timeline

• Start date: 2009-09-01
• Primary completion: 2012-02-01
• Completion: 2012-08-01
• First posted: 2008-09-09
• Last updated: 2009-08-11

Locations

1 site across 1 country: Israel